Precision Genomics for Transplant Care: 300 Monthly Analyses, 2-Day Turnaround, 9.3% Diagnostic Breakthroughs

• Our client is a precision medicine company in California focusing on transplant patient healthcare.
• The client aimed to improve kidney transplant care and graft survival using genetic testing.
• Strand developed a two-phase in silico pipeline that processes approximately 300 samples monthly with a 2-day turnaround, aiding clinicians in CKD and pharmacogenetic decision-making.
• In a study with 3315 CKD patients, exome sequencing identified diagnostic variants in 9.3% of the patients, demonstrating the genetic diversity of hereditary nephropathies.